Grzegorz Nowakowski, MD
Grzegorz (Greg) S. Nowakowski, M.D., is a consultant and a Professor of Oncology and Medicine, Division of Hematology. He also serves as the Deputy Director of Mayo Clinic Comprehensive Cancer Center for Clinical Research and the Vice-Chair of Division of Hematology.
Dr. Nowakowski is an internationally recognized researcher and leader. His research focuses on the molecular classification and biology of lymphoproliferative disorders, new approaches to clinical trial design and novel therapies for lymphoma and hematological disorders. He is a principal investigator for multiple investigator-initiated and cooperative-group clinical trials (ECOG, Alliance) and industry-sponsored and investigator-initiated studies. He is a member of the ECOG Lymphoma Core Committee, chair of the American Society of Hematology (ASH) Clinical Trial Innovation Subcommittee, co-Chair of the ASH-FDA Regulatory Science Workshop, and chair of the American Society of Clinical Oncology (ASCO) Clinical Trial Access and Participation Taskforce.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Daiichi Sankyo, Inc.Date added:09/29/2023Date updated:09/29/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Karyopharm TherapeuticsDate added:09/29/2023Date updated:09/29/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Kite Pharma, Inc.Date added:09/29/2023Date updated:09/29/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Karyopharm TherapeuticsDate added:09/29/2023Date updated:09/29/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Bantam Pharmaceutical, LLCDate added:09/29/2023Date updated:09/29/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Zai LaboratoryDate added:09/29/2023Date updated:09/29/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Kymera TherapeuticsDate added:09/29/2023Date updated:09/29/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:TG Therapeutics, IncDate added:09/29/2023Date updated:09/29/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Blueprint Medicines CorporationDate added:09/29/2023Date updated:09/29/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Constellation PharmaceuticalsDate added:09/29/2023Date updated:09/29/2023